IR@PKUHSC  > 北京大学第三临床医学院  > 药剂科
学科主题临床医学
Cabergoline for preventing ovarian hyperstimulation syndrome
Tang, Huilin1; Hunter, Tamara2; Hu, Yongfang1; Zhai, Suo-Di1; Sheng, Xiaoyan1; Hart, Roger J3,4
刊名COCHRANE DATABASE OF SYSTEMATIC REVIEWS
2012
DOI10.1002/14651858.CD008605.pub2
2
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]ENDOTHELIAL GROWTH-FACTOR ; DOPAMINE AGONISTS ; OHSS DEVELOPMENT ; VEGF SECRETION ; IVF PATIENTS ; STIMULATION ; WOMEN ; BROMOCRIPTINE ; PROLACTIN ; RISK
英文摘要

Background

Ovarian hyperstimulation syndrome (OHSS) is a complication resulting from administration of human chorionic gonadotrophin (hCG) in assisted reproduction technology (ART) treatment. Most case are mild, but forms of moderate or severe OHSS appear in 3% to 8% of in vitro fertilisation (IVF) cycles. Recently, the dopamine agonist cabergoline has been introduced as a secondary prevention intervention for OHSS in women at high risk of OHSS who are undergoing ART treatment.

Objectives

To assess the effectiveness and safety of cabergoline in preventing ovarian hyperstimulation syndrome (OHSS) in high-risk women undergoing ART treatment.

Search methods

Majormedical databases (CochraneMenstrualDisorders and SubfertilityGroup SpecialisedRegister of trials,CENTRAL (TheCochrane Library), MEDLINE, EMBASE and PsycINFO) were systematically searched for randomised controlled trials (RCTs) assessing the effect of cabergoline in preventing OHSS. Databases were searched up to September 2011. Registers of clinical trials, abstracts of scientific meetings and reference lists of included studies were searched. No language restrictions were applied.

Selection criteria

RCTs which compared cabergoline with placebo, no treatment or another intervention for preventing OHSS in high-risk women were considered for inclusion. Primary outcome measures included incidence of moderate or severe OHSS and live birth rate. Secondary endpoints were clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and any other adverse effects of the treatment.

Data collection and analysis

Two authors independently screened titles, abstracts and the full text of publications; extracted data; and assessed risk of bias. Any disagreements were resolved by consensus. Pooled results were reported as odds ratio (OR) and 95% confidence interval (95% CI) by the Mantel-Haenszel method.

Main results

Only two trials involving 230 women met the inclusion criteria. Both studies had a moderate risk of bias. Oral cabergoline, 0.5 mg daily, was given as an intervention and compared with a matched placebo. A statistically significant reduction in OHSS was observed in the cabergoline treated group (OR 0.40, 95% CI 0.20 to 0.77; 2 RCTs, 230 women) with a number needed to treat (NTT) of 7. There was a statistically significant difference in the incidence of moderate OHSS, favouring cabergoline (OR 0.38, 95% CI 0.19 to 0.78; 2 RCTs, 230 women) but not in severe OHSS (OR 0.77, 95% CI 0.24 to 2.45; 2 RCTs, 230 women). There was no significant difference in the clinical pregnancy rate (OR 0.94, 95% CI 0.56 to 1.59; 2 RCTs, 230 women), miscarriage rate (OR 0.31, 95% CI 0.03 to 3.07; 1 RCT, 163 women) or any other adverse effects of the treatment (OR 2.07, 95% CI 0.56 to 7.70; 1 RCT, 67 women). However, no data on multiple pregnancy rate or live birth rate were reported in either trial.

Authors′ conclusions

Cabergoline appears to reduce the risk of OHSS in high-risk women, especially for moderate OHSS. The use of cabergoline does not affect the pregnancy outcome (clinical pregnancy rate, miscarriage rate), nor is there an increased risk of adverse events. Further research should consider the risk of administering cabergoline and the comparison between cabergoline and established treatments (such as intravenous albumin and coasting). Large, well-designed and well-executed RCTs that involve more clinical endpoints are necessary to further evaluate the role of cabergoline in OHSS prevention.

语种英语
WOS记录号WOS:000301187200050
引用统计
被引频次:15[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66336
专题北京大学第三临床医学院_药剂科
作者单位1.Peking Univ, Hosp 3, Dept Pharm, Therapeut Drug Monitoring & Clin Toxicol Ctr, Beijing 100191, Peoples R China
2.King Edward Mem Hosp, Dept Obstet & Gynaecol, Perth, WA, Australia
3.Univ Western Australia, King Edward Mem Hosp, Sch Womens & Infants Hlth, Subiaco, WA, Australia
4.Fertil Specialists Western Australia, Subiaco, WA, Australia
推荐引用方式
GB/T 7714
Tang, Huilin,Hunter, Tamara,Hu, Yongfang,et al. Cabergoline for preventing ovarian hyperstimulation syndrome[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2012(2).
APA Tang, Huilin,Hunter, Tamara,Hu, Yongfang,Zhai, Suo-Di,Sheng, Xiaoyan,&Hart, Roger J.(2012).Cabergoline for preventing ovarian hyperstimulation syndrome.COCHRANE DATABASE OF SYSTEMATIC REVIEWS(2).
MLA Tang, Huilin,et al."Cabergoline for preventing ovarian hyperstimulation syndrome".COCHRANE DATABASE OF SYSTEMATIC REVIEWS .2(2012).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Tang, Huilin]的文章
[Hunter, Tamara]的文章
[Hu, Yongfang]的文章
百度学术
百度学术中相似的文章
[Tang, Huilin]的文章
[Hunter, Tamara]的文章
[Hu, Yongfang]的文章
必应学术
必应学术中相似的文章
[Tang, Huilin]的文章
[Hunter, Tamara]的文章
[Hu, Yongfang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。